PCaVision (Angiogenesis Analytics)
Angiogenesis Analytics is developing PCaVision, an ultrasound-based computer-aided diagnosis system for prostate cancer. Their solution aims to provide results within minutes, at a cost-effective price, and offers optimal care pathways for patients with full diagnostic control for the provider, without the need for an MRI scan. PCaVision analyzes 3D B-mode, elastography, and contrast-enhanced ultrasound images to produce heatmaps indicating potentially cancerous regions for targeted biopsies. The procedure is designed to be performed by urologists or healthcare professionals at outpatient clinics without specialized training. The company is on track for European and US release in Q3 2025, with worldwide release by 2028. European clinical trials are underway, and preparations for US and Asian trials are in progress. PCaVision is currently for investigational use only, pending regulatory market-access activities.
PCaVision (Angiogenesis Analytics)
Angiogenesis Analytics is developing PCaVision, an ultrasound-based computer-aided diagnosis system for prostate cancer. Their solution aims to provide results within minutes, at a cost-effective price, and offers optimal care pathways for patients with full diagnostic control for the provider, without the need for an MRI scan. PCaVision analyzes 3D B-mode, elastography, and contrast-enhanced ultrasound images to produce heatmaps indicating potentially cancerous regions for targeted biopsies. The procedure is designed to be performed by urologists or healthcare professionals at outpatient clinics without specialized training. The company is on track for European and US release in Q3 2025, with worldwide release by 2028. European clinical trials are underway, and preparations for US and Asian trials are in progress. PCaVision is currently for investigational use only, pending regulatory market-access activities.